Dr. Abdallah on blenrep combo approval in relapsed myeloma
In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the
Multiple Myeloma
Video Interviews
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves epcoritamab combo in R/R follicular lymphoma
The US Food and Drug Administration (FDA) approved epcoritamab (EPKINLY) in combination with rituximab, lenalidomide, and lenalidomide (RLL) for adult patients with relapsed
Ambassador Program
News
Society Updates
SOHO Egypt 2025 debuts with 2-day meeting in Cairo
The inaugural SOHO-EGYPT Meeting (November 5 to 6) was a joint session within NCI's BGO 2025 Congress ("Bridging Gaps in Oncology," November 5
Multiple Myeloma
News
Society Updates
Young Investigator Program
SOHO Young Investigator spotlight: Meet Maha Hameed, MD
As a resident physician who is fascinated by hematologic malignancies, Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive
Ambassador Program
News
Society Updates
SOHO KSA holds 3rd successful regional meeting
SOHO KSA held its first regional meeting in Riyadh, the Kingdom of Saudi Arabia (KSA). The two-day event was held at the Intercontinental
Multiple Myeloma
DARZALEX FASPRO® gets FDA approval to treat HR-smoldering multiple myeloma
The US Food and Drug Administration has approved daratumumab co-formulated with hyaluronidase (DARZALEX FASPRO®), as a single-agent therapy for adults with high-risk smoldering multiple
Multiple Myeloma
News
US FDA grants interchangeable designation for denosumab-bnht
The US Food and Drug Administration (FDA) granted interchangeable biosimilar designation to denosumab-bnht (Bomyntra) for patients with multiple myeloma (MM) to prevent skeletal-related
SOHO 2025
Leukemia
Chronic Lymphocytic Leukemia
Meetings / Conferences
News
SOHO pilot program finds structured learning improves practice in R/R CLL/SLL
At the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), a new pilot program debuted to educate and empower the
Leukemia News
SOHO 2025
News
Video Interviews
How does MRD guide treatment decisions in ALL?
Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center, moderates a discussion on acute lymphoblastic leukemia (ALL) MRD-guided
Lymphoma
T-Cell Lymphoma
News
Targeted immune CTCL therapy set for US launch in Q4 2025
Citius Oncology has entered a distribution services agreement with McKesson Corporation for denileukin diftitox-cxdl (LYMPHIR), a novel immunotherapy, for adult patients with relapsed